UCLA scientists develop a new approach for a flu vaccine

| By | Development of Vaccines, Drug Development, R&D

A radical new approach for a flu vaccine is being developed at UCLA (University of California, Los Angeles). The scientists used leading-edge genomics to identify and eliminate the virus’s defense mechanisms, enabling them to develop a vaccine “candidate” — meaning that it must still undergo evaluation and approval by the FDA — that in animals has been proven to be safe and highly effective against influenza.

In the study, which was published in the journal Science, the engineered influenza virus induced strong immune responses in animals. While further research will be needed, the UCLA scientists are hopeful that their approach could lead to a new, more effective vaccine that can be taken as a nasal spray at home, rather than as an injection by a health professional.

“Because the variations of seasonal influenza viruses can be unpredictable, current vaccines may not provide effective protection against them,” said Ren Sun, a professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA and the study’s senior author. “Previous pandemics and recent outbreaks of avian influenza highlight the need to develop vaccines that offer broader, more effective protection.”

The key to the new vaccine is an understanding of the interactions between the virus and interferons, which are proteins that are critical to the body’s immune response. Interferons have two main functions: one is a first line of defense to kill invading viruses very quickly; a second is to coordinate the adaptive immune responses, which provide long-lasting protection against the virus. The latter is the basis of vaccination.

Sun and colleagues have spent the past four years searching the influenza virus’s entire genome for its anti-interferon properties. After defining the function of every amino acid in the genome, they deactivated the sequences that prevent interferon induction, which meant that interferon production would be highly stimulated in organisms infected with the virus.

Ren Sun and his colleagues now plan to test the vaccine in animals with two strains of influenza before moving to clinical trials with humans. He said the approach could also be applied to developing vaccines against a wide range of other viruses.

SOURCE: ucla
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.